{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:30:26Z","timestamp":1789601426538,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Diffuse podocytopathy (DP) is a clinical and pathological entity, which comprises minimal change disease and primary focal segmental glomerulosclerosis (FSGS). It is characterized by diffuse podocyte foot process effacement resulting in nephrotic syndrome. Cumulative evidence supports that DP is a complex disease caused by circulating permeability factors. Following kidney transplantation, DP may recur and severely compromise graft survival. However, prior studies aiming to define immune and genetic factors implicated in disease recurrence have been limited by small cohorts and lack of utilizing stringent criteria to define DP. In this report, we briefly review the important advances made in understanding genomic and permeability factors involved in DP in the native kidney and in the transplant setting, focusing on anti-nephrin antibodies. We stress the importance of applying stringent criteria to define patients at risk of post-transplant recurrence and share our experience in a cohort of 281 consecutive kidney transplant recipients with native kidney failure attributed to FSGS or other forms of DP. Applying strict clinicopathologic criteria combining nephrotic syndrome and diffuse foot process effacement at the time of native kidney biopsy to define DP markedly increased recurrence rate from 9% to 36%. Excluding selected patients with monogenic forms of FSGS and those with high-risk\n                    <jats:italic>APOL1<\/jats:italic>\n                    genotypes further increased recurrence rate to 54%. In conclusion, an accurate diagnosis of DP in the native kidney is crucial to further our understanding of genomic and immunologic predictors of DP recurrence and to ultimately support the development of prophylactic or therapeutic regimens to improve allograft outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1735978","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:56:19Z","timestamp":1769064979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Opportunities and challenges in recurrent diffuse podocytopathy post-transplantation: the critical value of the definition"],"prefix":"10.3389","volume":"17","author":[{"given":"Rachel","family":"Nuccitelli","sequence":"first","affiliation":[{"name":"Department of Surgery, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadea","family":"Toutoungis","sequence":"additional","affiliation":[{"name":"Department of Pathology & Cell Biology, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Sanna-Cherchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Weins","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mass General Brigham and Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather K.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Batal","sequence":"additional","affiliation":[{"name":"Department of Pathology & Cell Biology, Columbia University Irving Medical Center","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"771931","DOI":"10.3389\/fcell.2021.771931","article-title":"Controversies in podocyte loss: death or detachment","volume":"9","author":"Yin","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.akdh.2024.10.004","article-title":"Podocytopathies","volume":"32","author":"Navarro-Torres","year":"2025","journal-title":"Adv Kidney Dis Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.ki.5002655","article-title":"Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts)","volume":"73","author":"D\u2019Agati","year":"2008","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000499","article-title":"Minimal change disease and FSGS are a spectrum of a single disease within immune-mediated nephrotic syndrome","volume":"5","author":"Sim","year":"2024","journal-title":"Kidney360"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196907242810402","article-title":"Progression of \u201clipoid nephrosis\u201d to renal insufficiency","volume":"281","author":"Hayslett","year":"1969","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i17.5861","article-title":"Transition from minimal change disease to focal segmental glomerulosclerosis related to occupational exposure: A case report","volume":"10","author":"Tang","year":"2022","journal-title":"World J Clin Cases"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03531006","article-title":"Adult minimal-change disease: clinical characteristics, treatment, and outcomes","volume":"2","author":"Waldman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1124249","article-title":"The role of HLA antigens in recurrent primary focal segmental glomerulosclerosis","volume":"14","author":"Batal","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2025.06.19","article-title":"What\u2019s new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney","volume":"59","author":"Weins","year":"2025","journal-title":"J Pathol Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology","volume":"33","author":"Watts","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.003","article-title":"Clinical characteristics of nephrin autoantibody-positive minimal change disease in older adults","volume":"9","author":"Fujita","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.02.028","article-title":"Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis","volume":"108","author":"Shu","year":"2025","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000001102","article-title":"New insights into the biology and treatment of minimal change disease and focal segmental glomerulosclerosis","volume":"34","author":"Barr","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.019","article-title":"Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy","volume":"107","author":"Hengel","year":"2025","journal-title":"Kidney Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000642","article-title":"Anti-slit antibodies against podocin and kirrel1 in pediatric and adult podocytopathies","volume":"36","author":"Raglianti","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","article-title":"A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation","volume":"6","author":"Delville","year":"2014","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017111185","article-title":"Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome","volume":"29","author":"Debiec","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.05.029","article-title":"Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome","volume":"98","author":"Jia","year":"2020","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41467-023-37985-w","article-title":"Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome","volume":"14","author":"Barry","year":"2023","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.20233411S1306b","article-title":"A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence","volume":"105","author":"Shirai","year":"2023","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfu100","article-title":"Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations","volume":"7","author":"Sethi","year":"2014","journal-title":"Clin Kidney J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.6002\/ect.MESOT2021.O24","article-title":"Primary focal segmental glomerulosclerosis recurrence after pediatric renal transplantation","volume":"20","author":"Baskin","year":"2022","journal-title":"Exp Clin Transpl"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12825","article-title":"Focal segmental glomerulosclerosis in pediatric kidney transplantation: 30 years\u2019 experience","volume":"30","author":"Cleper","year":"2016","journal-title":"Clin Transpl"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829c2431","article-title":"Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk","volume":"96","author":"Nehus","year":"2013","journal-title":"Transplantation"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.21311","article-title":"Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States","volume":"37","author":"Abbott","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.09.005","article-title":"Steroid-resistant nephrotic syndrome is associated with a unique genetic profile in a highly admixed pediatric population","volume":"9","author":"Watanabe","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013080852","article-title":"Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence","volume":"25","author":"Ding","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-018-4103-3","article-title":"Correction to: Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings: A Midwest Pediatric Nephrology Consortium (MWPNC) study","volume":"34","author":"Pelletier","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.07.022","article-title":"Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft","volume":"106","author":"Batal","year":"2024","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e748","DOI":"10.1097\/TXD.0000000000001201","article-title":"HLA loci and recurrence of focal segmental glomerulosclerosis in pediatric kidney transplantation","volume":"7","author":"Shaw","year":"2021","journal-title":"Transplant Direct"},{"key":"B38","doi-asserted-by":"publisher","first-page":"12008","DOI":"10.1038\/s41598-021-91520-9","article-title":"Degree of foot process effacement in patients with genetic focal segmental glomerulosclerosis: a single-center analysis and review of the literature","volume":"11","author":"Ishizuka","year":"2021","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000534853","article-title":"Monogenic causes identified in 23.68% of children with steroid-resistant nephrotic syndrome: A single-centre study","volume":"10","author":"Zhang","year":"2024","journal-title":"Kidney Dis (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000069","article-title":"Rapid progression of focal segmental glomerulosclerosis in patients with high-risk APOL1 genotypes","volume":"18","author":"Kallash","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2369-14-47","article-title":"A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation","volume":"14","author":"Maas","year":"2013","journal-title":"BMC Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6832971","DOI":"10.1155\/2016\/6832971","article-title":"Recurrence and treatment after renal transplantation in children with FSGS","volume":"2016","author":"Kang","year":"2016","journal-title":"BioMed Res Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735978\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:44:53Z","timestamp":1771919093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735978\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1735978"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735978","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"1735978"}}